

BD Veritor meets new FDA flu requirements, 5/17

May 2017—Becton Dickinson announced that its BD Veritor System Flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new FDA performance requirements in which antigen-based rapid influenza virus antigen detection systems (RIDTs) intended to detect influenza virus directly from clinical specimens have been reclassified from class I devices to class II devices subject to special controls.

The now-class II BD Veritor System Flu A+B test first became available in 2011 and is the same test used on the new BD Veritor Plus System, a next-generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus, and group A strep.

[**BD**](#), 201-847-6800